Parker Moss - Exscientia Executive Development
| EXAIDelisted Stock | USD 4.84 0.00 0.00% |
Executive
Parker Moss is Executive Development of Exscientia Ltd ADR
| Phone | 44 18 6581 8941 |
| Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Exscientia Ltd ADR currently holds 18.92 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Exscientia ADR has a current ratio of 8.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Exscientia's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Richard Mulligan | Sana Biotechnology | 69 | |
| MS MBA | PDS Biotechnology Corp | 59 | |
| Michael Naso | Century Therapeutics | N/A | |
| Erin Graves | Revolution Medicines | N/A | |
| Federico MD | Unity Biotechnology | 51 | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Alexander Azoy | Unity Biotechnology | 48 | |
| Cynthia MD | Leap Therapeutics | 55 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Kristen MBA | Recursion Pharmaceuticals | N/A | |
| MD BA | Adaptimmune Therapeutics Plc | 61 | |
| Przemyslaw Sapieha | Unity Biotechnology | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Jason Baum | Leap Therapeutics | 46 | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Jayanthi Wolf | Atea Pharmaceuticals | N/A | |
| Jeanne Gray | Relay Therapeutics | N/A | |
| Paul MD | Sana Biotechnology | N/A | |
| Adel Moussa | Atea Pharmaceuticals | N/A | |
| JD Esq | Kymera Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.46 | |||
| Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Overington, Chief Officer | ||
| Eileen JenningsBrown, Chief Officer | ||
| Ben AshwellFryer, VP Fin | ||
| Parker Moss, Executive Development | ||
| Ben Taylor, Chief CFO | ||
| CBE DPHIL, CEO Founder | ||
| Nikolaus Krall, Executive Medicine | ||
| Dan Ireland, Executive Secretary | ||
| Heather Togwell, Operations Mang | ||
| Caroline Rowland, Chief Officer | ||
| Chris Thomas, VP People | ||
| Garry Pairaudeau, Chief Officer | ||
| MarieLouise MD, Interim Lead | ||
| FRSE DPHIL, CEO Founder | ||
| David Hallett, Interim Officer | ||
| Michael MD, Chief Officer | ||
| Margo Mosley, VP Operations | ||
| Richard Law, Chief Officer | ||
| Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | |||
| Return On Asset | -0.21 | |||
| Operating Margin | (10.66) % | |||
| Current Valuation | 346.92 M | |||
| Shares Outstanding | 130.82 M | |||
| Shares Owned By Insiders | 25.90 % | |||
| Shares Owned By Institutions | 20.80 % | |||
| Number Of Shares Shorted | 2.81 M | |||
| Price To Book | 1.95 X | |||
| Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |